Literature DB >> 8286622

Cryptococcal meningitis and AIDS.

W G Powderly1.   

Abstract

Dr. William G. Powderly provides a comprehensive review of the state of our knowledge regarding cryptococcal infection in persons with infection due to human immunodeficiency virus type 1. The introduction of fluconazole and itraconazole increased insight into prognostic factors affecting these patients. The need to suppress this fungal infection in individuals with impaired immunity has greatly altered the management of cryptococcal meningitis; therapy for this condition was established by the landmark study conducted by the Mycosis Study Group in 1979 (Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-31). In this AIDS commentary Dr. Powderly clearly outlines the progress made through clinical investigations and the problems that remain to be resolved.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8286622     DOI: 10.1093/clinids/17.5.837

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  64 in total

Review 1.  HTLV-1 and HIV infections of the central nervous system in tropical areas.

Authors:  P Cabre; D Smadja; A Cabié; C R Newton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

2.  Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection.

Authors:  Sarah E Hardison; Karen L Wozniak; Jay K Kolls; Floyd L Wormley
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

3.  Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.

Authors:  M Del Poeta; D L Toffaletti; T H Rude; C C Dykstra; J Heitman; J R Perfect
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

Review 4.  The role of medical imaging in defining CNS abnormalities associated with HIV-infection and opportunistic infections.

Authors:  David F Tate; Rola Khedraki; Daniel McCaffrey; Daniel Branson; Jeffrey Dewey
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

5.  Cryptococcal Meningitis in HIV-Infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

6.  Chronic Meningitis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

7.  Characterization of a flocculation-like phenotype in Cryptococcus neoformans and its effects on pathogenesis.

Authors:  Li Li; Oscar Zaragoza; Arturo Casadevall; Bettina C Fries
Journal:  Cell Microbiol       Date:  2006-06-07       Impact factor: 3.715

8.  Decreased resistance to primary intravenous Cryptococcus neoformans infection in aged mice despite adequate resistance to intravenous rechallenge.

Authors:  K M Aguirre; G W Gibson; L L Johnson
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Cysteinyl leukotrienes as novel host factors facilitating Cryptococcus neoformans penetration into the brain.

Authors:  Longkun Zhu; Ravi Maruvada; Adam Sapirstein; Marc Peters-Golden; Kwang Sik Kim
Journal:  Cell Microbiol       Date:  2016-09-25       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.